672883-68-0

Basic information

• Product Name: 3-(cyclopropylMethoxy)-4-(difluoroMethoxy)benzoyl chloride
• Synonyms: 3-(cyclopropylMethoxy)-4-(difluoroMethoxy)benzoyl chloride
• CAS NO: 672883-68-0
• Molecular Formula: C₁₂H₁₁ClF₂O₃
• Molecular Weight: 276.6637464
• Mol File: 672883-68-0.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 352.84°C at 760 mmHg
• Flash Point: 144.06°C
• Appearance: /
• Density: 1.354g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.519
• CAS DataBase Reference: 3-(cyclopropylMethoxy)-4-(difluoroMethoxy)benzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(cyclopropylMethoxy)-4-(difluoroMethoxy)benzoyl chloride(672883-68-0)
• EPA Substance Registry System: 3-(cyclopropylMethoxy)-4-(difluoroMethoxy)benzoyl chloride(672883-68-0)

Safety Data

• Hazardous Substances Data: 672883-68-0(Hazardous Substances Data)

Usage

General Description

3-(cyclopropylMethoxy)-4-(difluoroMethoxy)benzoyl chloride is a chemical compound with the molecular formula C12H10ClF2O3. It is a benzoyl chloride derivative with a cyclopropylMethoxy group at the 3-position and a difluoroMethoxy group at the 4-position. 3-(cyclopropylMethoxy)-4-(difluoroMethoxy)benzoyl chloride is commonly used in organic synthesis as a reagent for the introduction of the benzoyl group and can be utilized in the preparation of various pharmaceutical and agrochemical compounds. It is important to handle this compound with caution, as it is a reactive and potentially hazardous substance.

InChI:InChI=1/C12H11ClF2O3/c13-11(16)8-3-4-9(18-12(14)15)10(5-8)17-6-7-1-2-7/h3-5,7,12H,1-2,6H2

Upstream product

• 25934-52-5 3-(cyclopropylmethoxy)-4-hydroxybenzaldehyde 
• 1381886-14-1 4-(benzyloxy)-3-(cyclopropylmethoxy)benzaldehyde 
• 4049-39-2 4-benzyloxy-3-hydroxy-benzaldehyde 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 151103-09-2 3-(cyclopropylmethoxy)-4-(difluoromethoxy)-benzaldehyde 
• 151103-08-1 4-difluoromethoxy-3-hydroxybenzaldehyde 
• 162401-62-9 3-(cyclopropylmethoxy)-4-(difluoromethoxy)-benzoic acid 

Downstream Products

• 672883-67-9 (3S)-3-(3-cyclopropylmethyloxy-4-difluoromethoxyphenylcarboxamido)-2,6-dioxo-hexahydropyridine 
• 672883-84-0 (3S)-3-(3-cyclopropylmethyloxy-4-difluoromethoxyphenylcarboxamido)-2-oxohexahydro-pyridine 
• 672883-90-8 (3S)-3-(3-cyclopropylmethyloxy-4-difluoromethoxyphenylcarboxamido)-2-oxo-1-phenyl-hexahydropyridine 
• 672883-96-4 (3S)-3-(3-cyclopropylmethyloxy-4-difluoromethoxyphenylcarboxamido)-6-oxo-hexahydropyridine 
• 672884-01-4 (3S)-3-(3-cyclopropylmethyloxy-4-difluoromethoxyphenylcarboxamido)-6-oxo-1-phenyl-hexahydropyridine 
• 162401-32-3 roflumilast 

Relevant articles and documents

Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease

Considering the importance of PDE4D inhibition and the modulation of biometals in Alzheimer's disease (AD) therapeutics, we have designed, synthesized and evaluated a series of new clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands fo

Synthesis and molecular docking of new roflumilast analogues as preferential-selective potent PDE-4B inhibitors with improved pharmacokinetic profile

In the present work, we designed and synthesized new roflumilast analogues with preferential-selective PDE-4B inhibition activity and improved pharmacokinetic properties. The unsubstituted benzo[d]thiazol-2-yl and -6-yl benzamide derivatives (4a and 6a) showed both good potency and preferential selectivity for PDE-4B. More remarkably, 6c revealed 6 times preferential PDE-4B/4D selectivity with a significant increase of in vitro cAMP and good % inhibition of TNF-α concentration. In addition, the in vitro pharmacokinetics of 6c showed good metabolic stability with in vitro CLint (5.67 mL/min/kg) and moderate % plasma protein binding (53.71%). This was reflected onto increased in vivo exposure with a half-life greater than roflumilast by 3 folds (21 h) and a Cmax value of 113.958 ng/mL. Molecular docking attributed its good activity to its key binding interactions in PDE-4B active site with additional hydrogen bonding with amino acids lining the metal pocket. Summing up, 6c can be considered as suitable candidate for further investigation for the treatment of COPD.

Discovery of N-Alkyl Catecholamides as Selective Phosphodiesterase-4 Inhibitors with Anti-neuroinflammation Potential Exhibiting Antidepressant-like Effects at Non-emetic Doses

Depression involving neuroinflammation is one of the most common disabling and life-threatening psychiatric disorders. Phosphodiesterase 4 (PDE4) inhibitors produce potent antidepressant-like and cognition-enhancing effects. However, their clinical utilit